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Background: [18F]HX4 is a promising new PET tracer developed to identify hypoxic
areas in tumor tissue. This study analyzes [18F]HX4 kinetics and assesses the
performance of simplified methods for quantification of [18F]HX4 uptake.
To this end, eight patients with non-small cell lung cancer received dynamic
PET scans at three different time points (0, 120, and 240 min) after injection of
426 ± 72 MBq [18F]HX4, each lasting 30 min. Several compartment models were
fitted to time activity curves (TAC) derived from various areas within tumor
tissue using image-derived input functions.
Results: Best fits were obtained using the reversible two-tissue compartment
model with blood volume parameter (2T4k+VB). Simplified measures correlated
well with VT estimates (tumor-to-blood ratio (TBr) R
2 = 0.96, tumor-to-muscle ratio
R2 = 0.94, standardized uptake value R2 = 0.89).
Conclusions: [18F]HX4 shows reversible kinetics in tumor tissue: 2T4k+VB. TBr
based on static imaging at 2 or 4 h can be used for quantification of [18F]HX4
uptake.
Keywords: 18F-3-Fluoro-2-(4-((2-Nitro-1H-Imidazol-1-yl)Methyl)-1H-1,2,3-Triazol-1-yl)
Propan-1-ol ([18F]HX4), Hypoxia, Molecular imaging, Positron emission tomography
(PET), Non-small cell lung cancer (NSCLC), Tracer kinetic modeling, Standardized uptake
value (SUV), Tumor-to-blood ratio, Image-derived input function (IDIF)Background
Tumor tissue often exhibits insufficient or abnormal vasculature, leading to reduced
delivery of oxygen and nutrients to tumor cells. Decreased pO2 tension (“hypoxia”) can
lead to upregulation of hypoxia inducible factor-1 (HIF-1), promoting tumor cell
survival as well as tumor growth and metastatic potential [1]. Tumor targeted therapy
strategies, such as radiation therapy and many types of chemotherapy, require the
presence of oxygen in the cell [2, 3]. Tumor hypoxia is therefore an important
predictor of overall survival and response to therapy [4]. Advanced treatment strat-
egies for specifically targeting hypoxic tumor cells [5, 6], such as hypoxia-specificThe Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
icense (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
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being evaluated in clinical trials. For correct diagnosis as well as successful application of
these advanced treatment strategies, accurate assessment of oxygenation status and
the heterogeneous distribution of hypoxia in tumor tissue are required.
The gold standard for assessing tissue oxygenation is the polarographic needle electrode.
However, this method is invasive and limited to accessible lesions. Furthermore, it is not
suitable for visualizing the heterogeneous distribution of hypoxia within the tumor, which
would be required for radiation therapy dose painting. Positron emission tomography (PET)
allows for non-invasive in vivo imaging of tumor tissue characteristics, making this
technique suitable for both identification of the presence of hypoxia as well as for
assessing the heterogeneous distribution.
Several hypoxia-specific PET tracers have been developed. Most are based on a
nitroimidazole group which is bioreduced upon entering the cell and retained in
hypoxic cells, when rapid re-oxidation does not occur. The most evaluated hypoxia
tracer is 18F-fluoromisonidazole ([18F]FMISO) [12], which shows slow clearance
from normoxic tissue, likely due to its lipophilicity, necessitating long time intervals
between injection of the tracer and imaging.
The novel nitroimidazole-based PET tracer, 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-
1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol ([18F]HX4), is reported to be relatively
hydrophilic [13]. This characteristic facilitates fast clearance from normoxic tissues,
thus enhances image contrast [14]. [18F]HX4 also shows favorable characteristics with
respect to robustness; metabolite formation is reported to be very limited, with parent
fractions of 82% remaining after 2 h in human plasma [15].
The hypoxia specificity of [18F]HX4 uptake has been verified in a preclinical setting
[13]. However, to be able to use PET imaging to assess tumor hypoxia levels, quantifi-
cation of tracer uptake in the tissue is required. Full pharmacokinetic modeling using
dynamic PET imaging can be used to accurately quantify the tracer uptake. However,
due to the elaborate imaging protocol required for full pharmacokinetic modeling, a
simplified method (such as the standardized uptake value (SUV) which is based on a
PET image acquired with a static imaging protocol) is often preferred in a routine clin-
ical setting. In fact, several published papers on [18F]HX4 use these simplified methods
for quantification of tracer uptake [16–19]. The validity of these simplified methods
has, however, not yet been established for [18F]HX4. The aim of the current paper was
to study the kinetics of [18F]HX4 using pharmacokinetic modeling and to assess the
validity of several commonly used simplified parameters for quantifying [18F]HX4 up-
take by comparing their performance to full pharmacokinetic modeling results. To this
end, dynamic PET studies, each study consisting of three 30-min dynamic PET scans
and spanning of 4.5 h in total, were obtained from patients diagnosed with non-small
cell lung cancer (NSCLC) and analyzed.Methods
Inclusion criteria
Patients were recruited from the PET-Boost trial (NCT01024829) [20]. Included were
patients with pathologically proven NSCLC stages T2-4, N0-3, and M0. Further
inclusion criteria were minimal primary tumor diameter of 4 cm, ECOG
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take value (SUV) ≥5 for the primary tumor. Exclusion criteria were radiotherapy
to the thorax prior to PET/CT imaging, tumor growth in large blood vessels, and post-
obstructive atelectasis or infiltration that cannot be distinguished from tumor
tissue on a PET/CT scan. The study was approved by the competent Medical
Ethical Review Committee, and each patient signed informed consent after verbal
and written explanation.Synthesis of [18F]HX4
The precursor for the synthesis of [18F]HX4 was provided by the Threshold
Pharmaceuticals, San Francisco, USA. Cyclotron-produced 18F was worked up under
standard conditions with Kryptofix [2.2.2] and K2CO3 and used for the radiolabeling of
[18F]HX4 at 110 °C for 5 min in 1 mL of a 50/50 mixture of t-butanol/acetonitrile. Subse-
quent acidic hydrolysis with HCl (5 min at 105 °C) yielded the product. [18F]HX4 was
purified with semiprep HPLC (ACE 5 AQ, 250 × 10 mm, 10 μm, eluent: water/aceto-
nitrile/formic acid 95/5/0.1). The fraction containing the product was isolated and diluted
with 20 mL of water for injection and passed over a Sep-Pak HLB cartridge (Waters,
Etten-Leur, The Netherlands) to trap the product. After washing the cartridge with
10 mL of water for injection, the product was eluted with 1 mL of sterile ethanol and
10 mL of a solution of 7.1 mM NaH2PO4 in saline (pH 5.2) through a Millex GV
0.22 μm filter (Merck Millipore, Darmstadt, Germany) into a sterile vial to yield a
sterile and pyrogen-free solution with radiochemical purity >97% and specific activity
11–136 GBq/μmol at time of injection.Data acquisition
PET/CT imaging was performed on a Gemini TF64 PET/CT scanner (Philips Healthcare,
Cleveland, USA) with spatial resolution ~7 mm FWHM. For each scan, the patient was
positioned on a flat tabletop using a laser alignment system with both arms above the
head in a dedicated radiotherapy arm-support system. First, a 30-min dynamic PET scan
was acquired, starting simultaneously with intravenous injection of 426 ± 72 MBq
[18F]HX4 [16]. Afterwards, the patient returned for two additional 30 min dynamic scans
at 2 and 4 h p.i. Each PET scan was preceded by a low dose CT with matrix dimensions
of 512 × 512 × 45 voxels (1.17 × 1.17 × 4.00 mm3) for attenuation and scatter correc-
tion purposes and anatomical information. PET data were corrected for decay, dead
time, attenuation, and scatter and reconstructed using a three-dimensional row action max-
imum likelihood reconstruction algorithm (3-D RAMLA) into 32, 6, and 6 frames,
respectively (10 × 6 s, 6 × 20 s, 4 × 30 s, 5 × 60 s, 5 × 120 s, 2 × 300 s; 6 × 300 s; 6 ×
300 s) of matrix dimensions 144 × 144 × 45 voxels (4 × 4 × 4 mm3). All data were re-
constructed in concordance with guidelines for quantitative [18F] fluorodeoxyglu-
cose PET studies [21, 22].
PET images at 2 and 4 h p.i. were co-registered to the last PET frame of the first
dynamic scan (acquired 25–30 min p.i.) using a rigid co-registration algorithm in
the software program Vinci (version 2.56.0; Max Planck Institute for Metabolism
Research, Cologne, Germany). The three co-registered PET scans were then
concatenated to provide one dynamic PET scan with a total time span of 4.5 h.
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fied by visually inspecting the full scan and time activity curves (TAC).Kinetic analysis
Extraction of time activity curves
For each patient, up to five volumes of interest (VOI) were defined manually within the
largest primary tumor structure. One whole-tumor VOI was defined on the low dose
CT of the first PET/CT scan (VOICT). Additionally, VOI were defined on the averaged
PET image acquired over time interval 4–4.5 h p.i.; to investigate possible differences
in kinetics within tumor tissue, up to three VOI were defined in areas showing
relatively high (VOIHigh), average (VOIAvg), and low (VOILow) PET signal, as determined
visually with the aid of thresholding. In addition, as most tumors featured an area with
markedly low PET signal, possibly indicating necrosis, a whole-tumor VOI was defined
where this area was excluded (VOIViable). For comparison, VOI in several healthy tissues
(muscle, lung, fat, and liver tissue; when visible within the PET field of view) were defined
manually onto the low dose CT image, taking care to avoid tissue boundary limits. All
VOI were defined by the same person and manually adjusted to exclude large blood pool
structures identified on early PET frames showing the tracer in the arterial blood vessels.
VOI were then projected onto the full dynamic PET scan to derive TAC.
Derivation of plasma input functions
For each patient, whole-blood TAC were derived from a VOI that was defined manually
within the ascending aorta, as identified using an early PET frame best displaying the
blood pool. All VOI were defined by the same person, and care was taken to obtain
large VOI (2.28 ± 0.99 cm3) whilst avoiding vessel boundaries. To derive metabolite-
corrected image-derived input functions (IDIF), the whole-blood TAC were interpo-
lated and corrected using population-based plasma-to-blood ratios and parent fraction
data obtained from an internal report, provided by Doss et al. [15], containing data
from three healthy volunteers for several time points up to 2 h p.i. As plasma-to-blood
ratios were reported to be equal to 1 and stable over time, correction for plasma-to-
blood ratio was omitted. Metabolite formation over time was estimated by fitting a
Hill function through all parent fraction data points reported. Whole-blood TAC were
then corrected for metabolites by multiplication with the resulting parent fraction
curve. As parent fraction data was limited to the first 2 h p.i., the accuracy of parent frac-
tion estimates extrapolated to 4 h p.i. might be reduced. Therefore, the analysis was con-
ducted twice, once for TAC spanning time interval 0–2.5 h p.i. and once for time interval
0–4.5 h p.i. In addition, to assess the impact of metabolite correction, the analyses were
repeated with non-corrected IDIF (IDIFWB).
Non-linear regression analysis
Several standard compartment models were fitted to all tissue TAC using non-linear
regression routines (NLR) using kinetic analysis software developed in MatLab
(MathWorks) at VU University Medical Center [23]. Models evaluated were the
reversible single-tissue compartment model (1T2k) and the irreversible and reversible
two-tissue compartment model (2T3k and 2T4k, respectively). Each model was evaluated
with and without correction for blood volume fraction (VB). Boundary conditions for all
estimated kinetic parameters were applied to prevent errors due to local cost function
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intervals: K1 [0.1], k2 [0.1], k3 [0.0.5], k3/k4 [0.5], and VB [0.0.25], yielding the results




−2λt , where L is the frame duration,T is the estimated total number of trues, λ is the
decay constant, and t is the frames mid time).
To investigate the effect of study duration, we have fully analyzed the dataset twice,
once including only data acquired over the first 0–2.5 h p.i. and once including the full
0–4.5 h data. In this paper, we will show the results for the 0–2.5 h dataset and discuss
the effect of including the 4–4.5 h data in the analysis.
The model best suited to describe the kinetics of [18F]HX4 in tumor tissue was
selected based on the Akaike information criterion (AIC) for small sample sizes
[24, 25] for all tumor VOI.
Validation of simplified parameters
Simplified parameters, e.g., standardized uptake value (SUV), using various normalization
factors (body weight (BW), lean body mass (LBM), body surface area (BSA) and body
mass index (BMI)), tumor-to-blood ratio (TBr), and tumor-to-muscle ratio (TMr), were
calculated from the averaged images of both the 2 h p.i. as well as the 4 h p.i. PET scan.
For all tumor VOI, these measures were then compared to quantitative pharmacokinetic
parameters derived with full kinetic modeling.Results
PET/CT scans from 8 patients (5 male, 3 female) were analyzed. Pathology indicated
adenocarcinoma (N = 4), squamous cell carcinoma (N = 3), and large cell carcinoma
(N = 1). Mean age of the patients was 64 years (range 51–82 years), mean weight
75 kg (range 56–93 kg), mean height 172 cm (range 154–180 cm), and mean size of
the CT-based whole-tumor VOI was 111 mL (range 29–208 mL). Injected activity
was 426 ± 72 MBq. All patients had been previously treated with at least one course
of chemotherapy, but PET/CT imaging was performed before the onset of external
beam radiation therapy.
Typical examples of acquired data are given in Fig. 1 (Additional File 1 shows the
VOI in these images). Heterogeneous [18F]HX4 uptake in tumor tissue was observed.
SUVBW and tissue-to-muscle and tissue-to-blood ratios at 2 and 4 h p.i. are shown in
Table 1 for various areas within the tumor and for several healthy tissues. High correlation
was found between tumor activity concentrations at 4 and 2 h (R2 = 0.93; ICC = 0.86).Pharmacokinetic modeling
AIC results are summarized in Table 2 for the 2.5 h dataset, analyzed with IDIF. Results
indicate reversible kinetics in tumor tissue with governing model 2T4k+VB. Typical ex-
amples of NLR fits to the “viable” whole-tumor TAC (0–2.5 h p.i.) are shown in Fig. 2
for several models evaluated. Inclusion of 4–4.5 h data did not change the overall
model preference (Additional File 2), and 2T4k+VB fits derived were equivalent to
2T4k+VB derived from 2.5 h data, with similar VT values (R
2 = 0.96). At 4 h p.i., the
2T4k+VB fit underestimated activity concentrations compared to measured TAC
(VOIViable) by 14.7 ± 7.7%, while the 2T3k+VB fit overestimated by 10.2 ± 7.4%. Omission of
the population-based metabolite correction did not lead to changes in model selection but
Fig. 1 Typical [18F]HX4 PET/CT images of a patient with NSCLC: a low dose CT; b, c, d averaged PET image
acquired over 25–30 min p.i., 119–149 min p.i., and 237–267 min p.i., respectively
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centrations at late time points were only marginally affected; activity concentration
estimates at 4 h p.i. obtained with metabolite correction were 0.74% higher for the
2T3k+VB model and 0.09% lower for the 2T4k+VB model than those obtained without
metabolite correction.Performance of simplified methods
For tumor tissue, simplified parameters correlated well to VT derived with 2T4k+VB, as
shown in Fig. 3. Best results for 2.5 h data were obtained with TBr (R2 = 0.96), followedTable 1 Study group averages of SUVBW and tissue-to-muscle (TiMr) and tissue-to-blood (TiBr)
ratios (±2 SD) at 2 h and 4 h p.i. for various tissues
Tissue type SUVBW TiMr TiBr
2 h 4 h 2 h 4 h 2 h 4 h
Fat 0.27 ± 0.07 0.18 ± 0.08 0.29 ± 0.05 0.28 ± 0.09 0.28 ± 0.06 0.27 ± 0.10
Liver 1.28 ± 0.40 1.02 ± 0.23 1.54 ± 0.61 1.93 ± 1.12 1.48 ± 0.62 1.88 ± 0.89
Lung 0.24 ± 0.11 0.16 ± 0.10 0.25 ± 0.08 0.24 ± 0.12 0.24 ± 0.08 0.23 ± 0.09
Muscle 0.95 ± 0.28 0.67 ± 0.34 – – 0.96 ± 0.18 0.98 ± 0.28
Tumor 0.93 ± 0.56 0.72 ± 0.56 0.98 ± 0.46 1.09 ± 0.82 0.93 ± 0.35 1.02 ± 0.45
Tumor, viable 1.07 ± 0.63 0.86 ± 0.67 1.12 ± 0.49 1.29 ± 0.98 1.07 ± 0.36 1.21 ± 0.52
Tumor, high 1.22 ± 0.75 1.04 ± 0.83 1.28 ± 0.71 1.61 ± 1.58 1.22 ± 0.54 1.50 ± 0.96
Tumor, mid 0.96 ± 0.66 0.74 ± 0.54 1.00 ± 0.55 1.12 ± 0.79 0.95 ± 0.43 1.05 ± 0.39
Tumor, low 0.39 ± 0.52 0.33 ± 0.40 0.43 ± 0.59 0.62 ± 1.04 0.41 ± 0.51 0.55 ± 0.70
Table 2 VOI size (cm3) and model preference (%) for [18F]HX4 kinetics in various tissues according
to AIC, based on the 2.5 h dynamic PET data
Model
Tissue type VOI size (cm3) 1T2k 2T3k 2T4k 1T2k+VB 2T3k+VB 2T4k+VB
Fat 3.7 ± 1.1 – – 25 12.5 50 12.5
Lung 20.1 ± 9.3 – – – 37.5 50 12.5
Muscle 4.5 ± 2.5 – 12.5 25 62.5 – –
Liver 17.1 ± 9.2 – 25 75 – – –
Tumor 111.4 ± 64.1 – – – – – 100
Tumor, viable 48.0 ± 27.2 – – – – – 100
Tumor, high 3.0 ± 2.8 – – 25 – 12.5 62.5
Tumor, mid 1.8 ± 0.8 – 12.5 25 – 37.5 25
Tumor, low 1.1 ± 0.2 – – – – 75 25
For clarity, values of 0% are not shown
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gated (SUVBW R
2 = 0.89, SUVBSA R
2 = 0.91, SUVLBM R
2 = 0.82, SUVBMI R
2 = 0.88).
The 4.5 h dataset yielded lower correlations (TBr R2 = 0.83, TMr R2 = 0.74, SUVBW
R2 = 0.76, SUVBSA R
2 = 0.78, SUVLBM R
2 = 0.67, SUVBMI R
2 = 0.84).
Discussion
In this study, [18F]HX4 kinetics over the course of 4.5 h after injection were studied
using dynamic PET imaging and pharmacokinetic modeling. Results indicate that a
reversible two-tissue compartment model best describes [18F]HX4 kinetics in tumor
tissue. Good correlation was found between simplified parameters and VT, indicating
that static imaging at 2 or 4 h p.i. is a suitable alternative to full pharmacokinetic modeling
for quantifying [18F]HX4 uptake.
Theoretically, the uptake mechanism of nitroimidazole would indicate an irreversible
model. Therefore, for [18F]FMISO, generally, an irreversible model is used for quantifica-
tion [26]. The data-driven method used for model selection in this paper found aFig. 2 Non-linear regression fits to a tumor time activity curve from the typical example displayed in Fig. 1
using several of the models evaluated. a Fits to 2.5 h TAC extrapolated to 5 h p.i. b Detailed view of the
first 9 min p.i.
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Fig. 3 a, b, c Averaged simplified measures at 2–2.5 h p.i. for all tumor VOI, compared to VT derived with
NLR from 0–2.5 h dynamic PET data using the 2T4k+VB model and IDIF: a standardized uptake value
normalized to patient weight (SUVBW), b tumor-to-blood ratio (TBr), c tumor-to-muscle ratio (TMr);
d TBr as measured at 4–4.5 h p.i. compared to VT derived from 0–4.5 h dynamic PET data
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partition coefficient. [18F]HX4 is more hydrophilic than [18F]FMISO, leading to faster
diffusion and clearance rates. This hypothesis is corroborated by the fact that our results
are consistent with pharmacokinetic modeling results published for the hypoxia tracer
[18F]FAZA [27], which, like [18F]HX4, is relatively hydrophilic compared to [18F]FMISO.
Nevertheless, the apparent discrepancy begs the question whether the tumor tissue analyzed
was in fact hypoxic. Although no tissue pO2 levels were measured, as this procedure is
highly invasive, the size of the tumors and presence of a core of limited to no uptake, does
suggest the presence of hypoxic areas.
A possible explanation is that large VOI uptake kinetics could have been errone-
ously identified as reversible due to uptake heterogeneity causing an apparent re-
versible component to the averaged TAC [28]. For this reason, smaller VOI with
different uptake levels were also evaluated, and also, these VOI kinetics were found
to be reversible. It should be noted that for VOI in areas of relatively low uptake,
model preference did seem to shift toward the 2T3k+VB model. This is to be
expected since, given the relatively small size of these VOI (Table 2) in combi-
nation with the low counts per voxel, the TAC will be noisier. This leads to
smaller differences between the residual sums obtained with the two-tissue compart-
ment models. In that case, AIC will indicate a preference for the model with the smaller
number of parameters, i.e., the 2T3k+VB model.
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the 4.5 h p.i. activity concentrations in some patients. This may in part explain the lower
correlations between simplified parameters and VT that were observed for 4.5 h data. The
discrepancy could be the result of small differences in image-derived activity concen-
tration due to co-registration errors. Although a laser alignment system together with
a dedicated arm-support system were used to ensure proper positioning, and co-
registration results were visually verified, small co-registration discrepancies are likely
to occur as the thorax area is highly flexible.
Another explanation could be the lack of data for the time intervals between
scans. 4.5 h dynamic imaging was deemed too great a burden on the patient.
Therefore, imaging was limited to three 30-min dynamic scans spanning 4.5 h. It
is conceivable that the shape of the fits would have changed somewhat had the full
4.5 h TAC been available. However, assuming that the first 30 min data provides
accurate estimates of K1 and k2, the 2T3k+VB model could only fit the 4.5 h data
by decreasing k3. This would lead to underestimation at 2 h p.i. The 2T4k+VB
model is better able to find a proper fit through the whole TAC.
In pharmacokinetic modeling, it is often assumed that metabolites remain in the
blood, and only parent tracer is able to enter the tissue. Plasma input functions are
therefore corrected for radiolabeled metabolites. However, for some tracers, metabolites
may enter the tissue. As [18F]HX4 metabolite formation rate is slow, tissue metabolite
accumulation in the tissue will be slow but could be large enough at 4 h to cause
distinguishably higher tumor activity concentrations. As 0–2.5 h parent fraction data
were extrapolated to 4.5 h p.i., it is possible that parent fraction estimates at 4.5 h p.i.
were overestimated. This, however, would not explain the observed discrepancy
between fit and TAC at 4.5 h p.i. As shown in the “Results” section, omitting metabolite
correction entirely led to only marginal changes in 4 h activity concentration estimates.
It is therefore unlikely that the inability of either model to fit the 4.5 h data is the result
of underestimation of the metabolite fractions.
Theoretically, the discrepancy could be caused by a 3rd tissue compartment showing
very slow irreversible trapping of the radiotracer. A (irreversible) three-tissue compartment
would then yield closer fits to the data. However, given that the discrepancies between TAC
and fit observed at 4 h p.i. are small, k5 would have to be so small that resulting NLR fits
will be unreliable even if full 4.5 h dynamic data were available. Yet, based on the data
presented in this study, possible influence of a third compartment cannot be excluded.
Such a conclusion would require dynamic PET imaging over exceptionally long imaging
times (>4.5 h), flawless co-registration of PET images, and voxel-by-voxel (to limit the
influence of averaging and co-registration errors on shape of the TAC), for instance, using
spectral analysis, a method that does not a priori assume a compartment model type [29].
To our best assessment, this type of study would be impossible to achieve in a clinical
setting. Theoretically, the third compartment would represent the hypoxia-specific uptake
mechanism. From the data, it is clear that contribution of this third compartment would
be very small while the observed increase in TMr over time does indicate a marked
difference in retention rates in certain tumor tissue areas compared to normoxic
(muscle) tissue. This seems to suggest that the second compartment already contains
a hypoxia-specific component (albeit reversible), and evaluation of hypoxia is possible
with [18F]HX4 PET within the imaging time interval used of the study.
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0.96 for VT values), and given the high correlation between simplified measures and VT
values, static imaging at 2 h p.i. may suffice for quantitative assessment of [18F]HX4
uptake. This would allow for a clinically more convenient imaging protocol. Yet, it
should be noted that imaging at 4 h p.i. would yield higher image contrast, mainly
because of better washout of [18F]HX4 in normoxic tissues, which may facilitate delineation
of high [18F]HX4 uptake areas. The use of very late (4 h p.i.) uptake images could be
of importance when [18F]HX4 PET imaging is performed for radiation oncology purpose
(e.g., definition of biological target volumes), but is less critical for quantification of tumor
VT. Performance of tumor delineation techniques is beyond the scope of this paper and
will be part of future research.
IDIF were corrected for plasma-to-blood ratio and metabolites based on population
averages based on data by Doss et al. [15]. Individual differences in metabolite formation
and plasma-to-blood ratio are not taken into account. For tracers exhibiting high
metabolite formation rate in combination with high variability between patients,
individual parent fraction correction would be required. Metabolite formation for
[18F]HX4 rate is shown to be slow in healthy subjects by Doss et al. [15]. Therefore,
individual differences in metabolite formation rate will likely cause only marginal
differences in parent fraction values. Furthermore, similar hypoxia PET tracers all
exhibit similarly slow metabolite formation rates in humans: [18F]FMISO [30],
[18F]FETNIM [31], [18F]EF5 [32], and [18F]FAZA [27]. Robustness of [18F]HX4 in
patients should be confirmed in a larger study population. Nevertheless, as metabolites
are assumed to remain in the blood stream, differences in metabolism would affect TBr
and SUV values. It cannot be assumed that the effect is similar to its effect on VT values
derived with metabolite-corrected plasma input functions, which may in part explain the
somewhat lower correlation between TBr and VT for the 4.5 h dataset for which extrapo-
lated metabolite data was used (Fig. 3d). However, the fact that correlations between TBr
and SUV with VT derived with uncorrected input functions were high, does suggest that
differences in parent fractions and plasma-to-blood ratios between patients were small
and would not affect the conclusions presented in this paper.
Conclusions
[18F]HX4 kinetics can best be described by a reversible two-tissue compartment model.
Most accurate simplified parameter is tumor-to-blood ratio. These quantitative metrics
can be obtained without dynamic imaging, using a static (whole body) imaging protocol
at either 2 or 4 h p.i.
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